118 related articles for article (PubMed ID: 23121858)
1. Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder.
Amital D; Fostick L; Silberman A; Calati R; Spindelegger C; Serretti A; Juven-Wetzler A; Souery D; Mendlewicz J; Montgomery S; Kasper S; Zohar J
Eur Neuropsychopharmacol; 2013 Aug; 23(8):895-901. PubMed ID: 23121858
[TBL] [Abstract][Full Text] [Related]
2. The economic impact of depression: resistance or severity?
Fostick L; Silberman A; Beckman M; Spivak B; Amital D
Eur Neuropsychopharmacol; 2010 Oct; 20(10):671-5. PubMed ID: 20624674
[TBL] [Abstract][Full Text] [Related]
3. Serious life events among resistant and non-resistant MDD patients.
Amital D; Fostick L; Silberman A; Beckman M; Spivak B
J Affect Disord; 2008 Oct; 110(3):260-4. PubMed ID: 18262654
[TBL] [Abstract][Full Text] [Related]
4. Treatment resistant depression and axis I co-morbidity.
Petersen T; Gordon JA; Kant A; Fava M; Rosenbaum JF; Nierenberg AA
Psychol Med; 2001 Oct; 31(7):1223-9. PubMed ID: 11681548
[TBL] [Abstract][Full Text] [Related]
5. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
Akiskal HS; Benazzi F; Perugi G; Rihmer Z
J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
[TBL] [Abstract][Full Text] [Related]
6. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
[TBL] [Abstract][Full Text] [Related]
7. Treatment-resistant depression and Axis II comorbidity.
Petersen T; Hughes M; Papakostas GI; Kant A; Fava M; Rosenbaum JF; Nierenberg AA
Psychother Psychosom; 2002; 71(5):269-74. PubMed ID: 12207107
[TBL] [Abstract][Full Text] [Related]
8. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study.
Souery D; Oswald P; Massat I; Bailer U; Bollen J; Demyttenaere K; Kasper S; Lecrubier Y; Montgomery S; Serretti A; Zohar J; Mendlewicz J;
J Clin Psychiatry; 2007 Jul; 68(7):1062-70. PubMed ID: 17685743
[TBL] [Abstract][Full Text] [Related]
9. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
10. Negative impact of migraine on quality of life after 4 weeks of treatment in patients with major depressive disorder.
Hung CI; Liu CY; Yang CH; Wang SJ
Psychiatry Clin Neurosci; 2012 Feb; 66(1):8-16. PubMed ID: 22250605
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of treatment resistant depression among major depressive disorder patients in Israel.
Sharman Moser S; Chodick G; Gelerstein S; Barit Ben David N; Shalev V; Stein-Reisner O
BMC Psychiatry; 2022 Aug; 22(1):541. PubMed ID: 35948895
[TBL] [Abstract][Full Text] [Related]
12. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials.
Iovieno N; Tedeschini E; Ameral VE; Rigatelli M; Papakostas GI
Int Clin Psychopharmacol; 2011 Mar; 26(2):69-74. PubMed ID: 20962663
[TBL] [Abstract][Full Text] [Related]
13. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
14. Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities.
Gaynes BN
J Clin Psychiatry; 2009; 70 Suppl 6():10-5. PubMed ID: 19922739
[TBL] [Abstract][Full Text] [Related]
15. Differential criterion functioning of alcohol use symptomatology in major depressive disorder?
Lynskey MT; Agrawal A
Psychol Med; 2008 Mar; 38(3):441-9. PubMed ID: 17935644
[TBL] [Abstract][Full Text] [Related]
16. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant response and subthreshold bipolarity in "unipolar" major depressive disorder: implications for practice and drug research.
Rihmer Z; Dome P; Gonda X
J Clin Psychopharmacol; 2013 Aug; 33(4):449-52. PubMed ID: 23775059
[No Abstract] [Full Text] [Related]
18. MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study.
Amsterdam JD; Shults J
J Affect Disord; 2005 Dec; 89(1-3):183-8. PubMed ID: 16213594
[TBL] [Abstract][Full Text] [Related]
19. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
[TBL] [Abstract][Full Text] [Related]
20. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
